Not Signed In - Ruboxistaurin Reduced Vision Loss In Patients With Moderate To Severe Non-Proliferative Diabetic Retinopathy In A New Study
Tue, 14 Nov 2006 08:00 AM EST
... Eli Lilly and Company (NYSE: LLY) today announced results from a three-year phase 3 clinical trial in which ruboxistaurin mesylate (proposed brand name Arxxant(TM), pronounced ark-ZONT) reduced the risk of sustained moderate vision loss by 40 percent when compared to placebo in patients with moderate to severe non-proliferative diabetic retinopathy (DR). [click link for full article] ...
Related Topics
- Retinopathy
- Low Vision
- Diabetic Diet
- Low Vision & Blindness
- Severe vision loss
- Diabetic Foot
- Diabetic retinopathy
- Diabetic Neuropathy
- Eyes and Vision
- Cervical Dysplasia
- Hearing Loss
- Vision Loss
- Decrease or loss of vision
- Permanent vision loss in the affected eye
- Permanent loss of vision, speech, movement
- Severe memory loss
- Severe loss of blood from the GI tract
- Pregnancy Loss
- Vision Impairment
- Osteoporosis
email this page
print this page
bookmark this page
feedback on this page
